1342 related articles for article (PubMed ID: 33129442)
1. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
2. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
[TBL] [Abstract][Full Text] [Related]
3. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X; Hauser SL; Kappos L; Arnold DL; Bar-Or A; Comi G; de Seze J; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Rammohan KW; Selmaj K; Traboulsee A; Sauter A; Masterman D; Fontoura P; Belachew S; Garren H; Mairon N; Chin P; Wolinsky JS;
N Engl J Med; 2017 Jan; 376(3):209-220. PubMed ID: 28002688
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
[TBL] [Abstract][Full Text] [Related]
5. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
6. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
[TBL] [Abstract][Full Text] [Related]
7. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
Fox EJ; Markowitz C; Applebee A; Montalban X; Wolinsky JS; Belachew S; Fiore D; Pei J; Musch B; Giovannoni G
Mult Scler; 2018 Dec; 24(14):1862-1870. PubMed ID: 30415593
[TBL] [Abstract][Full Text] [Related]
8. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.
Wolinsky JS; Montalban X; Hauser SL; Giovannoni G; Vermersch P; Bernasconi C; Deol-Bhullar G; Garren H; Chin P; Belachew S; Kappos L
Ann Neurol; 2018 Oct; 84(4):527-536. PubMed ID: 30155979
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
[TBL] [Abstract][Full Text] [Related]
11. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Hauser SL; Bar-Or A; Weber MS; Kletzl H; Günther A; Manfrini M; Model F; Mercier F; Petry C; Wing Q; Koendgen H; Smith T; Kappos L
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36792367
[TBL] [Abstract][Full Text] [Related]
12. Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.
Butzkueven H; Spelman T; Horakova D; Hughes S; Solaro C; Izquierdo G; Kubala Havrdová E; Grand'Maison F; Prat A; Girard M; Hupperts R; Onofrj M; Lugaresi A; Taylor B; ; Giovannoni G; Kappos L; Hauser SL; Montalban X; Craveiro L; Freitas R; Model F; Overell J; Muros-Le Rouzic E; Sauter A; Wang Q; Wormser D; Wolinsky JS
Eur J Neurol; 2022 Apr; 29(4):1082-1090. PubMed ID: 33724638
[TBL] [Abstract][Full Text] [Related]
13. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
Chisari CG; Bianco A; Brescia Morra V; Calabrese M; Capone F; Cavalla P; Chiavazza C; Comi C; Danni M; Filippi M; Iaffaldano P; Lanzillo R; Lo Fermo S; Lucisano A; Lugaresi A; Lus G; Marfia GA; Marinelli F; Mirabella M; Moiola L; Perin C; Realmuto S; Toscano S; Trojano M; Vecchio D; Patti F;
Neurotherapeutics; 2023 Oct; 20(6):1696-1706. PubMed ID: 37610702
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
[TBL] [Abstract][Full Text] [Related]
16. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
Hauser SL; Kappos L; Arnold DL; Bar-Or A; Brochet B; Naismith RT; Traboulsee A; Wolinsky JS; Belachew S; Koendgen H; Levesque V; Manfrini M; Model F; Hubeaux S; Mehta L; Montalban X
Neurology; 2020 Sep; 95(13):e1854-e1867. PubMed ID: 32690791
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
Cadavid D; Mellion M; Hupperts R; Edwards KR; Calabresi PA; Drulović J; Giovannoni G; Hartung HP; Arnold DL; Fisher E; Rudick R; Mi S; Chai Y; Li J; Zhang Y; Cheng W; Xu L; Zhu B; Green SM; Chang I; Deykin A; Sheikh SI;
Lancet Neurol; 2019 Sep; 18(9):845-856. PubMed ID: 31285147
[TBL] [Abstract][Full Text] [Related]
18. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
19. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]